[New indications and therapeutic objectives for dyslipidemia].
Maiques Galán
Antonio
A
D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001384:Azetidines / Q000008:administration & dosage / Q000627:therapeutic use; D008078:Cholesterol, LDL / Q000097:blood; D002986:Clinical Trials as Topic; D002995:Clofibric Acid / Q000008:administration & dosage / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D015195:Drug Design; D050171:Dyslipidemias / Q000188:drug therapy* / Q000517:prevention & control; D000069438:Ezetimibe; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000145:classification / Q000627:therapeutic use*; D012107:Research Design; D012116:Resins, Plant / Q000008:administration & dosage / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D001384:Azetidines; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D012116:Resins, Plant; D002995:Clofibric Acid; D000069438:Ezetimibe